Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Viking Therapeutics (NASDAQ: VKTX) reported its Q1 2023 financial results on April 26, 2023, highlighting significant developments in its clinical pipeline. The company completed enrollment in the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis, with data expected in Q2 2023. Viking also announced Phase 1 results for VK2735, showcasing up to 6% placebo-adjusted weight loss and a strong safety profile. The initiation of a Phase 1 trial for an oral formulation of VK2735 was also noted. Financially, Viking completed a public offering raising $287.5 million, enhancing its cash position to approximately $406 million. However, the net loss for the quarter increased to $19.5 million, or $0.25 per share, compared to a loss of $16.1 million, or $0.21 per share in 2022.